Search results
Showing 856 to 870 of 1517 results for patients and public
In development Reference number: GID-TA11718 Expected publication date: TBC
Evidence-based recommendations on tissue-cultured limbal stem cell allograft transplantation for regrowth of corneal epithelium. This involves taking limbal stem cells from a living or deceased donor, growing them in the laboratory and transplanting them onto the patient’s affected eye(s).
View recommendations for HTG139Show all sections
Sections for HTG139
Evidence-based recommendations on molnupiravir (Lagevrio) for treating mild to moderate COVID-19 in adults who have a positive SARS-CoV-2 test.
Avelumab for treating metastatic Merkel cell carcinoma (TA517)
Evidence-based recommendations on avelumab (Bavencio) for metastatic Merkel cell carcinoma in adults.
Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma (TA766)
Evidence-based recommendations on pembrolizumab (Keytruda) for adjuvant treatment of completely resected stage 3 melanoma in adults.
In development Reference number: GID-TA10998 Expected publication date: TBC
Awaiting development Reference number: GID-TA11626 Expected publication date: TBC
In development Reference number: GID-TA11615 Expected publication date: TBC
Awaiting development Reference number: GID-IPG10418 Expected publication date: TBC
In development Reference number: GID-TA11583 Expected publication date: TBC
In development Reference number: GID-TA11836 Expected publication date: TBC
Sacituzumab govitecan for untreated PD-L1-negative triple-negative advanced breast cancer [ID6433]
Awaiting development Reference number: GID-TA11489 Expected publication date: TBC
Navepegritide for treating achondroplasia in people 2 to 15 years [ID6538]
In development Reference number: GID-TA11699 Expected publication date: TBC
In development Reference number: GID-TA11658 Expected publication date: TBC
In development Reference number: GID-TA11801 Expected publication date: TBC